SCHEDULE: Vanguard Group Reports Zero Stake in Korro Bio Post-Realignment

The Vanguard Group filed an amended Schedule 13G, indicating zero beneficial ownership in Korro Bio Inc. following an internal realignment effective January 12, 2026.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G regarding its holdings in Korro Bio Inc.
• As of the event date March 13, 2026, The Vanguard Group reports 0% beneficial ownership of Korro Bio Inc.'s Common Stock.
• This change is due to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities held by these disaggregated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Korro Bio Inc. as it primarily reflects a procedural change in The Vanguard Group's reporting structure rather than a direct investment action or sentiment towards Korro Bio's performance.

Positives

• Increased transparency in beneficial ownership reporting due to disaggregation of Vanguard's holdings.

Negatives

• The Vanguard Group, as the parent entity, no longer holds any beneficial ownership in Korro Bio Inc. directly.

Risks

• NA

Future Outlook

The filing does not provide any forward-looking statements or guidance for Korro Bio Inc. It solely addresses a change in beneficial ownership reporting by The Vanguard Group.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• Securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects a procedural change in how large institutional investors like The Vanguard Group report their holdings, rather than a direct investment decision regarding Korro Bio Inc. This disaggregation of reporting is a common practice for large asset managers to comply with SEC regulations following internal structural changes.

Comparison to Industry Standards

• This filing is a standard regulatory update for a large institutional investor like The Vanguard Group, aligning with SEC Release No. 34-39538 (January 12, 1998) for disaggregated reporting.
• Similar reporting adjustments are made by other major asset managers such as BlackRock or State Street when their internal structures change, ensuring compliance with beneficial ownership rules.
• The 0% ownership reported by the parent entity, while subsidiaries report separately, is a common outcome of such realignments, not an unusual divestment.

Stakeholder Impact

• Shareholders (Korro Bio): No direct impact on Korro Bio's operations or valuation. The change is purely in who reports ownership, not necessarily a divestment from Vanguard's overall managed funds.
• Investors (Vanguard funds): No direct impact on the underlying investments within Vanguard's funds, as the securities are now reported by different entities within the Vanguard structure.

Next Steps

• Vanguard Group subsidiaries or business divisions will report beneficial ownership separately.

Key Dates

Recommendation

This Schedule 13G/A filing from The Vanguard Group is a procedural update reflecting an internal corporate realignment, not a change in investment strategy or a significant divestment from Korro Bio Inc. The reported 0% beneficial ownership by the parent entity is a result of disaggregated reporting by its subsidiaries. Therefore, it provides no new fundamental information about Korro Bio's prospects to warrant a change in an existing investment position. Investors should hold their current positions and look for filings from Vanguard's subsidiaries for actual beneficial ownership changes.

Keywords

Korro Bio Inc, Vanguard Group, Schedule 13G, beneficial ownership, common stock, internal realignment, SEC filing, investment adviser